Skye Bioscience Inc.

CBeyond(TM) will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab. Read the full article here: https://bit.ly/3T0hw8H

We're pleased to have broad sellside interest in nimacimab, our differentiated CB1 inhibitor focused on weight loss, and have a strong investment conference calendar through year-end.

Skye completed an informative obesity KOL event this morning with obesity experts and Skye management. Click here to see the webcast or PDF: https://bit.ly/4cSvP7j Skye also announced its updated "CBeyond" Phase 2 clinical trial design and its exploratory endpoint for sleep apnea in collaboration with Beacon Biosignals. Read the news release here: https://bit.ly/3WAqY4O

Don't forget to pre-register for Skye Bioscience's Obesity KOL event with obesity experts and Skye management starting this Wednesday at 9:00 am ET. Learn about peripheral CB1 inhibition's and Nimacimab's complementary positioning in the obesity therapeutic landscape. Join us and register here: https://bit.ly/4f1BMAh

Join Skye Bioscience for a virtual KOL Event featuring Louis J. Aronne, MD, FACP (Weill Cornell Medicine), Marcus DaSilva Goncalves, MD, PhD (NYU Langone Health), Lee M. Kaplan, MD, PhD (Geisel School of Medicine at Dartmouth), and Beverly Tchang, MD (Weill Cornell Medicine), who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism. Register at this link: https://bit.ly/4f1BMAh

The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024. Read the full article here: https://bit.ly/45XSWdZ

The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024. Read the full article here: https://bit.ly/45XSWdZ

“We are honored to unite these world-class obesity experts as we continue to advance the clinical development of Nimacimab for the treatment of obesity,” said Punit Dhillon, Chief Executive Officer and Chairman of Skye. “Their extensive scientific and clinical expertise will be instrumental in providing strategic oversight to support Skye as we expand our operations. We look forward to leveraging their guidance as we prepare to progress Nimacimab into a Phase 2 trial this quarter.” Read the full article here: https://bit.ly/4czOJPT

Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company’s operational and clinical expertise. Read the full article here: https://bit.ly/3LbCm0q

"We are pleased to be included in the Russell indexes, a widely recognized benchmark for small-cap stocks, which is a testament to Skye’s recent accomplishments,” said Kaitlyn Arsenault, CPA, CFO. Read the full article here: https://bit.ly/4cmCjLr